Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PtCl(phpy)(PTA)
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
PtCl(phpy)(PTA) is a cyclometallated platinum(II) complex featuring a 2-phenylpyridine (phpy) ligand and a 1,3,5-triaza-7-phosphaadamantane (PTA) phosphine ligand. This organometallic compound is part of a series of complexes designed to modulate biological activity through phosphine ligand substitution. Preclinical studies indicate that the PTA derivative possesses selective antileishmanial activity, significantly reducing infectivity in parasitic models, and selective antitumor activity against ovarian cancer cell lines. Its mechanism of action involves ligand exchange with sulfur- and nitrogen-containing biomolecules, as well as direct interaction with DNA and serum proteins like bovine serum albumin (BSA).
- Other names
- chloro(2-phenylpyridine)(1,3,5-triaza-7-phosphaadamantane)platinum(II)[Pt(II)(phpy)(PTA)Cl]
02
Targets
DNA
Beyond the preview
Go deeper on PtCl(phpy)(PTA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PtCl(phpy)(PTA).